Multiple Myeloma Clinical Trial
Official title:
A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer). The unique combination of activities of BKT140, i.e., the induction of the exit of blood cells such as stem cells and mature cells from the bone marrow to the peripheral blood, coupled with specific induction of MM cell death by BKT-140, represents a novel therapeutic strategy against MM.
The chemokine CXCL12 (also called SDF-1 - stromal-derived-factor-1) and its receptor, CXCR4
((CXC Chemokine Receptor 4), a molecule endowed with potent chemotactic activity for
hematopoietic cells, together play a pivotal role in the trafficking of hematopoietic stem
cells to the bone marrow 10,11. The CXCL12/CXCR4 axis is also critically involved in the
retention of hematopoietic cells within the BM microenvironment. Following chemotherapy and
irradiation, the CXCL12/CXCR4 axis delays the recovery of the BM progenitor cells and the
exit of mature cells such as neutrophils and monocytes to the periphery. Consequently,
disruption of the CXCL12/CXCR4 interaction results in mobilization of hematopoietic cells
including stem cells and a faster recovery of the treated BM.
BKT140 (4F-benzoyl-TN14003) is a highly selective and unique CXCR4 antagonist. Pre-clinical
studies showed that BKT140 binds CXCR4 with high affinity (1nM) 13. Biokine has demonstrated
the ability of the CXCR4 antagonist, BKT140, to mobilize various WBC such as neutrophils and
monocytes as well as progenitor and stem cells, from the BM. The ability of BKT140 to
stimulate the mobilization of these cells is superior to that of AMD3100, a CXCR4 antagonist
that is in clinical development for mobilization of stem cells in MM and lymphoma patients,
both qualitatively and quantitatively. BKT140 synergizes much more efficiently with G-CSF
when compared to AMD3100. Moreover, Biokine has shown that BKT140, in synergism with G-CSF
(NEUPOGEN®), is much more efficient in increasing the numbers of neutrophils and activated
monocytes in the blood, by several folds as compared to G-CSF alone. BKT140 also shortens
the neutropenic period due to an early release of neutrophils and monocytes from the BM.
More importantly, BKT140, in synergism with G-CSF, reduces the anemic period caused by
chemotherapy, due to a RBC production, which does not occur when G-CSF is given as a sole
treatment. More importantly, BKT140, but not G-CSF or AMD3100, is also capable of shortening
the period of cytopenia by boosting both the recovery of all hematopoietic cells in the BM
and their exit to the periphery, and therefore shortening the period of cytopenia following
chemotherapy or irradiation and BM transplantation. Importantly, Biokine has shown that upon
interaction with CXCR4, BKT140, but not AMD3100, selectively, specifically and rapidly
stimulates human leukemia and myeloma cell death in vitro and in vivo. Furthermore, BKT140
synergizes with other chemotherapeutic agents such as rapamycine to induce MM cell death.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |